Patents Expiring in December 2030
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marius | KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953-001 | Jul 27, 2022 | DISCN | Yes | No | 10,576,089 | ⤷ Start Trial | Y | METHOD OF TREATING TESTOSTERONE DEFICIENCY | |||
| Marius | KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953-001 | Jul 27, 2022 | DISCN | Yes | No | 10,576,090 | ⤷ Start Trial | Y | ||||
| Marius | KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953-001 | Jul 27, 2022 | DISCN | Yes | No | 11,590,146 | ⤷ Start Trial | Y | ||||
| Marius | KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953-002 | Jul 27, 2022 | RX | Yes | No | 10,576,089 | ⤷ Start Trial | Y | METHOD OF TREATING TESTOSTERONE DEFICIENCY | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
